HEPATIC BENEFITS OF SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS IN LIVER DISORDERS

Habib Yaribeygi; Mina Maleki; Tannaz Jamialahmadi; Seyed Adel Moallem; Amirhossein Sahebkar

doi:10.17179/excli2023-6022

HEPATIC BENEFITS OF SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS IN LIVER DISORDERS

Habib Yaribeygi, Mina Maleki, Tannaz Jamialahmadi, Seyed Adel Moallem, Amirhossein Sahebkar

Internal Medicine

Research output: Contribution to journal › Review article › peer-review

5 Citations (Scopus)

Abstract

Diabetic patients are at higher risk of liver dysfunction compared with the normal population. Thus, using hypo-glycemic agents to improve liver efficiency is important in these patients. Sodium-glucose cotransporters-2 inhib-itors (SGLT2i) are newly developed antidiabetic drugs with potent glucose-lowering effects. However, recent limited evidence suggests that they have extra-glycemic benefits and may be able to exert protective effects on the liver. Hence, these drugs could serve as promising pharmacological agents with multiple benefits against different hepatic disorders. In this review, the current knowledge about the possible effects of SGLT2 inhibitors on different forms of liver complications and possible underlying mechanisms are discussed.

Original language	English
Pages (from-to)	403-414
Number of pages	12
Journal	EXCLI Journal
Volume	22
DOIs	https://doi.org/10.17179/excli2023-6022
Publication status	Published - 2 Jan 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.17179/excli2023-6022Licence: CC BY

Cite this

@article{b9b93b2d746d435f9ef9014fef7c09c1,

title = "HEPATIC BENEFITS OF SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS IN LIVER DISORDERS",

abstract = "Diabetic patients are at higher risk of liver dysfunction compared with the normal population. Thus, using hypo-glycemic agents to improve liver efficiency is important in these patients. Sodium-glucose cotransporters-2 inhib-itors (SGLT2i) are newly developed antidiabetic drugs with potent glucose-lowering effects. However, recent limited evidence suggests that they have extra-glycemic benefits and may be able to exert protective effects on the liver. Hence, these drugs could serve as promising pharmacological agents with multiple benefits against different hepatic disorders. In this review, the current knowledge about the possible effects of SGLT2 inhibitors on different forms of liver complications and possible underlying mechanisms are discussed.",

keywords = "cirrhosis, Diabetes mellitus, fibrosis, hepatocellular carcinoma, liver, non-alcoholic fatty liver disorders, sodium-glucose cotransporter-2 inhibitors",

author = "Habib Yaribeygi and Mina Maleki and Tannaz Jamialahmadi and Moallem, {Seyed Adel} and Amirhossein Sahebkar",

year = "2023",

month = jan,

day = "2",

doi = "10.17179/excli2023-6022",

language = "English",

volume = "22",

pages = "403--414",

journal = "EXCLI Journal",

issn = "1611-2156",

publisher = "University of Mainz",

}

TY - JOUR

T1 - HEPATIC BENEFITS OF SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS IN LIVER DISORDERS

AU - Yaribeygi, Habib

AU - Maleki, Mina

AU - Jamialahmadi, Tannaz

AU - Moallem, Seyed Adel

AU - Sahebkar, Amirhossein

PY - 2023/1/2

Y1 - 2023/1/2

N2 - Diabetic patients are at higher risk of liver dysfunction compared with the normal population. Thus, using hypo-glycemic agents to improve liver efficiency is important in these patients. Sodium-glucose cotransporters-2 inhib-itors (SGLT2i) are newly developed antidiabetic drugs with potent glucose-lowering effects. However, recent limited evidence suggests that they have extra-glycemic benefits and may be able to exert protective effects on the liver. Hence, these drugs could serve as promising pharmacological agents with multiple benefits against different hepatic disorders. In this review, the current knowledge about the possible effects of SGLT2 inhibitors on different forms of liver complications and possible underlying mechanisms are discussed.

AB - Diabetic patients are at higher risk of liver dysfunction compared with the normal population. Thus, using hypo-glycemic agents to improve liver efficiency is important in these patients. Sodium-glucose cotransporters-2 inhib-itors (SGLT2i) are newly developed antidiabetic drugs with potent glucose-lowering effects. However, recent limited evidence suggests that they have extra-glycemic benefits and may be able to exert protective effects on the liver. Hence, these drugs could serve as promising pharmacological agents with multiple benefits against different hepatic disorders. In this review, the current knowledge about the possible effects of SGLT2 inhibitors on different forms of liver complications and possible underlying mechanisms are discussed.

KW - cirrhosis

KW - Diabetes mellitus

KW - fibrosis

KW - hepatocellular carcinoma

KW - liver

KW - non-alcoholic fatty liver disorders

KW - sodium-glucose cotransporter-2 inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85159046031&partnerID=8YFLogxK

U2 - 10.17179/excli2023-6022

DO - 10.17179/excli2023-6022

M3 - Review article

C2 - 37346806

AN - SCOPUS:85159046031

SN - 1611-2156

VL - 22

SP - 403

EP - 414

JO - EXCLI Journal

JF - EXCLI Journal

ER -

HEPATIC BENEFITS OF SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS IN LIVER DISORDERS

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this